Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) patients harboring a KRAS mutation have unfavorable therapeutic outcomes with chemotherapies, and the mutation also renders tolerance to immunotherapies. There is an unmet need for a new strategy for overcoming immunosuppression in KRAS-mutant NSCLC. The recently d...
Main Authors: | Yi-Chun Chao, Kang-Yun Lee, Sheng-Ming Wu, Deng-Yu Kuo, Pei-Wei Shueng, Cheng-Wei Lin |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/11/5649 |
Similar Items
-
Melatonin and Hippo Pathway: Is There Existing Cross-Talk?
by: Federica Lo Sardo, et al.
Published: (2017-09-01) -
Therapeutic effects of melatonin on cerebral ischemia reperfusion injury: Role of Yap-OPA1 signaling pathway and mitochondrial fusion
by: Na Wei, et al.
Published: (2019-02-01) -
Role of Hippo Signaling Pathway in Lung Cancer
by: Yuechao LIU, et al.
Published: (2017-09-01) -
Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer
by: Jessica M. Konen, et al.
Published: (2019-04-01) -
Downregulation of the PD-1/PD-Ls pathway in peripheral cells correlates with asbestosis severity
by: Meihua Qiu, et al.
Published: (2021-05-01)